112 results on '"Wälchli S"'
Search Results
2. Enhancement of tunnel safety in the Albula railway tunnel
- Author
-
Wälchli, S, primary and Bernet, C, additional
- Published
- 2013
- Full Text
- View/download PDF
3. Dendritic Cells Engineered to Express Defined Allo-HLA Peptide Complexes Induce Antigen-specific Cytotoxic T Cells Efficiently Killing Tumour Cells
- Author
-
Stronen, E., Abrahamsen, I. W., Gaudernack, G., Wälchli, S., Munthe, E., Buus, S., Johansen, F.-E., Lund-Johansen, F., and Olweus, J.
- Published
- 2009
- Full Text
- View/download PDF
4. Targeting allo-reactivity to leukaemia: O402
- Author
-
Abrahamsen, I., Stronen, E., Wälchli, S., Johansen, J., Gaudernack, G., Tjonnfjord, G., Kumari, S., Lund-Johansen, F., and Olweus, J.
- Published
- 2009
5. Tapping CD4 T cells for cancer immunotherapy
- Author
-
Inderberg, E.M., primary, Myhre, M.R., additional, Mensali, N., additional, Fåne, A., additional, Lislerud, K., additional, Kvalheim, G., additional, Gaudernack, G., additional, and Wälchli, S., additional
- Published
- 2016
- Full Text
- View/download PDF
6. Csk overexpression makes T cell dummy
- Author
-
Wälchli, S., primary, Inderberg, E.M., additional, Mensali, N., additional, Stenvik, B., additional, Oksvold, M., additional, Progida, C.A.M., additional, Bakke, O., additional, Fallang, L.-E., additional, Kvalheim, G., additional, and Myklebust, J.H., additional
- Published
- 2016
- Full Text
- View/download PDF
7. A universal killer T-cell for adoptive cell therapy of cancer
- Author
-
Wälchli, S., primary, Inderberg, E.M., additional, Myklebust, J.H., additional, Skorstad, G., additional, Myhre, M.R., additional, Faane, A., additional, Gaudernack, G., additional, and Kvalheim, G., additional
- Published
- 2015
- Full Text
- View/download PDF
8. Enhanced expression and anti-tumour activity of T cells engineered to express a cysteine-modified TCR targeting a frameshift mutation in MSI-HI colorectal cancer
- Author
-
Inderberg-Suso, E., primary, Wälchli, S., additional, Myhre, M.R., additional, Wang, M., additional, Almåsbak, H., additional, Kvalheim, G., additional, and Gaudernack, G., additional
- Published
- 2014
- Full Text
- View/download PDF
9. 20P - Csk overexpression makes T cell dummy
- Author
-
Wälchli, S., Inderberg, E.M., Mensali, N., Stenvik, B., Oksvold, M., Progida, C.A.M., Bakke, O., Fallang, L.-E., Kvalheim, G., and Myklebust, J.H.
- Published
- 2016
- Full Text
- View/download PDF
10. 11PD - Tapping CD4 T cells for cancer immunotherapy
- Author
-
Inderberg, E.M., Myhre, M.R., Mensali, N., Fåne, A., Lislerud, K., Kvalheim, G., Gaudernack, G., and Wälchli, S.
- Published
- 2016
- Full Text
- View/download PDF
11. Dendritic cells engineered to express defined allo-HLA peptide complexes induce antigen-specific cytotoxic T cells efficiently killing tumour cells
- Author
-
Stronen, E, Abrahamsen, I W, Gaudernack, G, Wälchli, S, Munthe, E, Buus, S, Johansen, F-E, Lund-Johansen, F, Olweus, J, Stronen, E, Abrahamsen, I W, Gaudernack, G, Wälchli, S, Munthe, E, Buus, S, Johansen, F-E, Lund-Johansen, F, and Olweus, J
- Abstract
Udgivelsesdato: 2009-Apr, Most tumour-associated antigens (TAA) are non-mutated self-antigens. The peripheral T cell repertoire is devoid of high-avidity TAA-specific cytotoxic T lymphocytes (CTL) due to self-tolerance. As tolerance is major histocompatibility complex-restricted, T cells may be immunized against TAA presented by a non-self human leucocyte antigen (HLA) molecule and transferred to cancer patients expressing that HLA molecule. Obtaining allo-restricted CTL of high-avidity and low cross-reactivity has, however, proven difficult. Here, we show that dendritic cells transfected with mRNA encoding HLA-A*0201, efficiently present externally loaded peptides from the antigen, Melan-A/MART-1 to T cells from HLA-A*0201-negative donors. CD8(+) T cells binding HLA-A*0201/MART-1 pentamers were detected already after 12 days of co-culture in 11/11 donors. The majority of cells from pentamer(+) cell lines were CTL and efficiently killed HLA-A*0201(+) melanoma cells, whilst sparing HLA-A*0201(+) B-cells. Allo-restricted CTL specific for peptides from the leukaemia-associated antigens CD33 and CD19 were obtained with comparable efficiency. Collectively, the results show that dendritic cells engineered to express defined allo-HLA peptide complexes are highly efficient in generating CTL specifically reacting with tumour-associated antigens.
- Published
- 2009
12. Identification of tyrosine phosphatases that dephosphorylate the insulin receptor. A brute force approach based on "substrate-trapping" mutants.
- Author
-
Wälchli, S, Curchod, M L, Gobert, R P, Arkinstall, S, and Hooft van Huijsduijnen, R
- Abstract
Many pharmacologically important receptors, including all cytokine receptors, signal via tyrosine (auto)phosphorylation, followed by resetting to their original state through the action of protein tyrosine phosphatases (PTPs). Establishing the specificity of PTPs for receptor substrates is critical both for understanding how signaling is regulated and for the development of specific PTP inhibitors that act as ligand mimetics. We have set up a systematic approach for finding PTPs that are specific for a receptor and have validated this approach with the insulin receptor kinase. We have tested nearly all known human PTPs (45) in a membrane binding assay, using "substrate-trapping" PTP mutants. These results, combined with secondary dephosphorylation tests, confirm and extend earlier findings that PTP-1b and T-cell PTP are physiological enzymes for the insulin receptor kinase. We demonstrate that this approach can rapidly reduce the number of PTPs that have a particular receptor or other phosphoprotein as their substrate.
- Published
- 2000
13. [Use of osteoarticular ultrasound by emergency physicians].
- Author
-
Wälchli S, Renard P, and Della Santa V
- Subjects
- Humans, Switzerland, Joint Diseases diagnostic imaging, Joint Diseases diagnosis, Emergency Medicine methods, Emergency Medicine education, Ultrasonography methods, Emergency Service, Hospital organization & administration
- Abstract
The use of ultrasound by emergency physicians is now well established. It can be integrated as an extension of the clinical examination, providing diagnostic support during consultation in the emergency department. However, its use in osteoarticular pathologies remains less frequent, despite a growing body of literature demonstrating its value in a variety of pathologies. Ultrasound is operator-dependent, so its proper use requires dedicated training. In Switzerland, training opportunities in osteoarticular ultrasound are still poorly known and not widely used by emergency physicians. This article describes the possibilities of use in the case of osteoarticular pathologies frequently encountered in emergency departments., Competing Interests: Les auteurs n’ont déclaré aucun conflit d’intérêts en relation avec cet article.
- Published
- 2024
- Full Text
- View/download PDF
14. CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
- Author
-
Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, and Wälchli S
- Subjects
- Humans, Animals, Mice, Tetraspanins immunology, Cell Line, Tumor, T-Lymphocytes immunology, Antigens, Differentiation, Myelomonocytic metabolism, Antigens, Differentiation, Myelomonocytic immunology, Female, Male, Antigens, Neoplasm, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute immunology, Leukemia, Myeloid, Acute pathology, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen metabolism, Immunotherapy, Adoptive methods
- Abstract
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed. Chimeric antigen receptor (CAR) T therapy has so far not been successful in AML due to lack of efficacy and safety. Indeed, the most attractive antigen targets are stem cell markers such as CD33 or CD123. We demonstrate that CD37, a mature B cell marker, is expressed in AML samples, and its presence correlates with the European LeukemiaNet (ELN) 2017 risk stratification. We repurpose the anti-lymphoma CD37CAR for the treatment of AML and show that CD37CAR T cells specifically kill AML cells, secrete proinflammatory cytokines, and control cancer progression in vivo. Importantly, CD37CAR T cells display no toxicity toward hematopoietic stem cells. Thus, CD37 is a promising and safe CAR T cell AML target., Competing Interests: Declaration of interests The CD37CAR construct has been patented (WO2017118745A1) and E.M.I., G.K., and S.W. are listed among the inventors. S.K. has received honoraria from TCR2 Inc., Miltenyi, Novartis, BMS, and GSK. S.K. is inventor of several patents in the field of immuno-oncology. S.K. received license fees from TCR2 Inc. and Carina Biotech. S.K. received research support from TCR2 Inc., Plectonic GmBH, Tabby Therapeutics, and Arcus Bioscience for work unrelated to this manuscript. The funding agencies had no role in the conduction and management of the presented research and were not involved in the preparation of this manuscript., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
15. Transient TCR-based T cell therapy in a patient with advanced treatment-resistant MSI-high colorectal cancer.
- Author
-
Maggadottir SM, Dueland S, Mensali N, Hamre H, Andresen PA, Myhre MR, Juul HV, Bigalke I, Lundby M, Hønnåshagen TK, Sæbøe-Larssen S, Josefsen D, Hagtvedt T, Wälchli S, Kvalheim G, and Inderberg EM
- Subjects
- Humans, Male, Immunotherapy, Adoptive methods, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Cytokines metabolism, Lymphocytes, Tumor-Infiltrating immunology, Lymphocytes, Tumor-Infiltrating metabolism, Treatment Outcome, T-Lymphocytes immunology, T-Lymphocytes metabolism, Middle Aged, Cytotoxicity, Immunologic, Colorectal Neoplasms therapy, Colorectal Neoplasms pathology, Colorectal Neoplasms genetics, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell metabolism, Microsatellite Instability
- Abstract
We previously demonstrated the antitumor effectiveness of transiently T cell receptor (TCR)-redirected T cells recognizing a frameshift mutation in transforming growth factor beta receptor 2. We here describe a clinical protocol using mRNA TCR-modified T cells to treat a patient with progressive, treatment-resistant metastatic microsatellite instability-high (MSI-H) colorectal cancer. Following 12 escalating doses of autologous T cells electroporated with in-vitro-transcribed Radium-1 TCR mRNA, we assessed T cell cytotoxicity, phenotype, and cytokine production. Tumor markers and growth on computed tomography scans were evaluated and immune cell tumor infiltrate at diagnosis assessed. At diagnosis, tumor-infiltrating CD8+ T cells had minimal expression of exhaustion markers, except for PD-1. Injected Radium-1 T cells were mainly naive and effector memory T cells with low expression of exhaustion markers, except for TIGIT. We confirmed cytotoxicity of transfected Radium-1 T cells against target cells and found key cytokines involved in tumor metastasis, growth, and angiogenesis to fluctuate during treatment. The treatment was well tolerated, and despite his advanced cancer, the patient obtained a stable disease with 6 months survival post-treatment. We conclude that treatment of metastatic MSI-H colorectal cancer with autologous T cells electroporated with Radium-1 TCR mRNA is feasible, safe, and well tolerated and that it warrants further investigation in a phase 1/2 study., Competing Interests: Declaration of interests G.K., S.W., and E.M.I. are inventors of intellectual property (WO2017194555)., (Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies.
- Author
-
Bobrowicz M, Kusowska A, Krawczyk M, Zhylko A, Forcados C, Slusarczyk A, Barankiewicz J, Domagala J, Kubacz M, Šmída M, Dostalova L, Marhelava K, Fidyt K, Pepek M, Baranowska I, Szumera-Cieckiewicz A, Inderberg EM, Wälchli S, Granica M, Graczyk-Jarzynka A, Majchrzak M, Poreba M, Gehlert CL, Peipp M, Firczuk M, Prochorec-Sobieszek M, and Winiarska M
- Subjects
- Humans, Cell Line, Tumor, Antigens, Neoplasm immunology, Antigens, Neoplasm genetics, Drug Resistance, Neoplasm drug effects, Antineoplastic Combined Chemotherapy Protocols pharmacology, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Doxorubicin pharmacology, Doxorubicin administration & dosage, Cyclophosphamide pharmacology, Cyclophosphamide therapeutic use, Vincristine pharmacology, Vincristine therapeutic use, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal therapeutic use, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen genetics, Receptors, Chimeric Antigen metabolism, Gene Expression Regulation, Neoplastic, Antigens, CD20 immunology, Antigens, CD20 metabolism, Antigens, CD20 genetics, Rituximab pharmacology, Rituximab therapeutic use, Tetraspanins genetics, Tetraspanins metabolism, Lymphoma, B-Cell immunology, Lymphoma, B-Cell therapy, Lymphoma, B-Cell genetics, Lymphoma, B-Cell drug therapy, Immunotherapy methods
- Abstract
Rituximab (RTX) plus chemotherapy (R-CHOP) applied as a first-line therapy for lymphoma leads to a relapse in approximately 40% of the patients. Therefore, novel approaches to treat aggressive lymphomas are being intensively investigated. Several RTX-resistant (RR) cell lines have been established as surrogate models to study resistance to R-CHOP. Our study reveals that RR cells are characterized by a major downregulation of CD37, a molecule currently explored as a target for immunotherapy. Using CD20 knockout (KO) cell lines, we demonstrate that CD20 and CD37 form a complex, and hypothesize that the presence of CD20 stabilizes CD37 in the cell membrane. Consequently, we observe a diminished cytotoxicity of anti-CD37 monoclonal antibody (mAb) in complement-dependent cytotoxicity in both RR and CD20 KO cells that can be partially restored upon lysosome inhibition. On the other hand, the internalization rate of anti-CD37 mAb in CD20 KO cells is increased when compared to controls, suggesting unhampered efficacy of antibody drug conjugates (ADCs). Importantly, even a major downregulation in CD37 levels does not hamper the efficacy of CD37-directed chimeric antigen receptor (CAR) T cells. In summary, we present here a novel mechanism of CD37 regulation with further implications for the use of anti-CD37 immunotherapies., Competing Interests: No potential conflict of interest was reported by the author(s)., (© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Published
- 2024
- Full Text
- View/download PDF
17. Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16.
- Author
-
Casey NP, Kleinmanns K, Forcados C, Gelebart PF, Joaquina S, Lode M, Benard E, Kaveh F, Caulier B, Helgestad Gjerde C, García de Jalón E, Warren DJ, Lindemann K, Rokkones E, Davidson B, Myhre MR, Kvalheim G, Bjørge L, McCormack E, Inderberg EM, and Wälchli S
- Subjects
- Female, Humans, Ovarian Neoplasms drug therapy, CA-125 Antigen metabolism, Membrane Proteins
- Abstract
Background: Ovarian cancer (OC) is the leading cause of death from gynecologic malignancies in the Western world. Contributing factors include a high frequency of late-stage diagnosis, the development of chemoresistance, and the evasion of host immune responses. Currently, debulking surgery and platinum-based chemotherapy are the treatment cornerstones, although recurrence is common. As the clinical efficacy of immune checkpoint blockade is low, new immunotherapeutic strategies are needed. Chimeric antigen receptor (CAR) T cell therapy empowers patients' own T cells to fight and eradicate cancer, and has been tested against various targets in OC. A promising candidate is the MUC16 ectodomain. This ectodomain remains on the cell surface after cleavage of cancer antigen 125 (CA125), the domain distal from the membrane, which is currently used as a serum biomarker for OC. CA125 itself has not been tested as a possible CAR target. In this study, we examined the suitability of the CA125 as a target for CAR T cell therapy., Methods: We tested a series of antibodies raised against the CA125 extracellular repeat domain of MUC16 and adapted them to the CAR format. Comparisons between these candidates, and against an existing CAR targeting the MUC16 ectodomain, identified K101 as having high potency and specificity. The K101CAR was subjected to further biochemical and functional tests, including examination of the effect of soluble CA125 on its activity. Finally, we used cell lines and advanced orthotopic patient-derived xenograft (PDX) models to validate, in vivo, the efficiency of our K101CAR construct., Results: We observed a high efficacy of K101CAR T cells against cell lines and patient-derived tumors, in vitro and in vivo. We also demonstrated that K101CAR functionality was not impaired by the soluble antigen. Finally, in direct comparisons, K101CAR, which targets the CA125 extracellular repeat domains, was shown to have similar efficacy to the previously validated 4H11CAR, which targets the MUC16 ectodomain., Conclusions: Our in vitro and in vivo results, including PDX studies, demonstrate that the CA125 domain of MUC16 represents an excellent target for treating MUC16-positive malignancies., Competing Interests: Competing interests: SW, EMI, DJW, NPC and EB have filled a patent application on chimeric antigen receptor for ovarian cancer. The other authors declare no conflict of interest., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
18. In vitro re-challenge of CAR T cells.
- Author
-
Klee CH, Villatoro A, Casey NP, Inderberg EM, and Wälchli S
- Subjects
- Humans, Cell Line, Receptors, Antigen, T-Cell metabolism, T-Lymphocytes metabolism, Signal Transduction
- Abstract
Chimeric antigen receptor (CAR) T cells (CAR T) have emerged as a potential therapy for cancer patients. CAR T cells are capable of recognizing membrane proteins on cancer cells which initiates a downstream signaling in T cells that ends in cancer cell death. Continuous antigen exposure over time, activation of inhibitory signaling pathways and/or chronic inflammation can lead to CAR T cell exhaustion. In this context, the design of CARs can have a great impact on the functionality of CAR T cells, on their potency and exhaustion. Here, using CD19CAR as model, we provide a re-challenge protocol where CAR T cells are cultured weekly with malignant lymphoid cell lines BL-41 and Nalm-6 to simulate them with continuous antigen pressure over a four-week period. This protocol can be value for assessing CAR T cell functionality and for the comparison of different CAR constructs., (Copyright © 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
19. Efficient chimeric antigen receptor targeting of a central epitope of CD22.
- Author
-
Casey NP, Klee CH, Fåne A, Caulier B, Graczyk-Jarzynka A, Krawczyk M, Fidyt K, Josefsson SE, Köksal H, Dillard P, Patkowska E, Firczuk M, Smeland EB, Winiarska M, Myklebust JH, Inderberg EM, and Wälchli S
- Subjects
- Humans, Antigens, CD19, Epitopes, Immunotherapy, Adoptive, Recurrence, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Receptors, Chimeric Antigen, Sialic Acid Binding Ig-like Lectin 2
- Abstract
Chimeric antigen receptor (CAR) T-cell therapy has had considerable success in the treatment of B-cell malignancies. Targeting the B-lineage marker CD19 has brought great advances to the treatment of acute lymphoblastic leukemia and B-cell lymphomas. However, relapse remains an issue in many cases. Such relapse can result from downregulation or loss of CD19 from the malignant cell population or expression of alternate isoforms. Consequently, there remains a need to target alternative B-cell antigens and diversify the spectrum of epitopes targeted within the same antigen. CD22 has been identified as a substitute target in cases of CD19-negative relapse. One anti-CD22 antibody-clone m971-targets a membrane-proximal epitope of CD22 and has been widely validated and used in the clinic. Here, we have compared m971-CAR with a novel CAR derived from IS7, an antibody that targets a central epitope on CD22. The IS7-CAR has superior avidity and is active and specific against CD22-positive targets, including B-acute lymphoblastic leukemia patient-derived xenograft samples. Side-by-side comparisons indicated that while IS7-CAR killed less rapidly than m971-CAR in vitro, it remains efficient in controlling lymphoma xenograft models in vivo. Thus, IS7-CAR presents a potential alternative candidate for the treatment of refractory B-cell malignancies., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the content of this article., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
20. Determination of CAR T cell metabolism in an optimized protocol.
- Author
-
Joaquina S, Forcados C, Caulier B, Inderberg EM, and Wälchli S
- Abstract
Adoptive transfer of T cells modified to express chimeric antigenic receptors (CAR) has emerged as a solution to cure refractory malignancies. However, although CAR T cell treatment of haematological cancers has now shown impressive improvement in outcome, solid tumours have been more challenging to control. The latter type is protected by a strong tumour microenvironment (TME) which might impact cellular therapeutic treatments. Indeed, the milieu around the tumour can become particularly inhibitory to T cells by directly affecting their metabolism. Consequently, the therapeutic cells become physically impeded before being able to attack the tumour. It is therefore extremely important to understand the mechanism behind this metabolic break in order to develop TME-resistant CAR T cells. Historically, the measurement of cellular metabolism has been performed at a low throughput which only permitted a limited number of measurements. However, this has been changed by the introduction of real-time technologies which have lately become more popular to study CAR T cell quality. Unfortunately, the published protocols lack uniformity and their interpretation become confusing. We herein tested the essential parameters to perform a metabolic study on CAR T cells and propose a check list of factors that should be set in order to draw sound conclusion., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Joaquina, Forcados, Caulier, Inderberg and Wälchli.)
- Published
- 2023
- Full Text
- View/download PDF
21. ALPL-1 is a target for chimeric antigen receptor therapy in osteosarcoma.
- Author
-
Mensali N, Köksal H, Joaquina S, Wernhoff P, Casey NP, Romecin P, Panisello C, Rodriguez R, Vimeux L, Juzeniene A, Myhre MR, Fåne A, Ramírez CC, Maggadottir SM, Duru AD, Georgoudaki AM, Grad I, Maturana AD, Gaudernack G, Kvalheim G, Carcaboso AM, de Alava E, Donnadieu E, Bruland ØS, Menendez P, Inderberg EM, and Wälchli S
- Subjects
- Child, Humans, Immunotherapy, Adoptive, T-Lymphocytes, Immunotherapy, Cell Line, Tumor, Alkaline Phosphatase, Osteosarcoma therapy, Bone Neoplasms therapy
- Abstract
Osteosarcoma (OS) remains a dismal malignancy in children and young adults, with poor outcome for metastatic and recurrent disease. Immunotherapies in OS are not as promising as in some other cancer types due to intra-tumor heterogeneity and considerable off-target expression of the potentially targetable proteins. Here we show that chimeric antigen receptor (CAR) T cells could successfully target an isoform of alkaline phosphatase, ALPL-1, which is highly and specifically expressed in primary and metastatic OS. The target recognition element of the second-generation CAR construct is based on two antibodies, previously shown to react against OS. T cells transduced with these CAR constructs mediate efficient and effective cytotoxicity against ALPL-positive cells in in vitro settings and in state-of-the-art in vivo orthotopic models of primary and metastatic OS, without unexpected toxicities against hematopoietic stem cells or healthy tissues. In summary, CAR-T cells targeting ALPL-1 show efficiency and specificity in treating OS in preclinical models, paving the path for clinical translation., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
22. Mechanism of CD79A and CD79B Support for IgM+ B Cell Fitness through B Cell Receptor Surface Expression.
- Author
-
Huse K, Bai B, Hilden VI, Bollum LK, Våtsveen TK, Munthe LA, Smeland EB, Irish JM, Wälchli S, and Myklebust JH
- Subjects
- Humans, Animals, Mice, Cell Count, Germinal Center, Immunoglobulin M, CD79 Antigens genetics, Receptors, Antigen, B-Cell genetics, B-Lymphocytes
- Abstract
The BCR consists of surface-bound Ig and a heterodimeric signaling unit comprised of CD79A and CD79B. Upon cognate Ag recognition, the receptor initiates important signals for B cell development and function. The receptor also conveys Ag-independent survival signals termed tonic signaling. Although the requirement of a CD79A/CD79B heterodimer for BCR complex assembly and surface expression is well established based on mice models, few studies have investigated this in human mature B cells. In this study, we found that human tonsillar B cells with high surface expression of IgM or IgG had potentiated BCR signaling compared with BCRlow cells, and high IgM expression in germinal center B cells was associated with reduced apoptosis. We explored the mechanism for IgM surface expression by CRISPR/Cas9-induced deletion of CD79A or CD79B in four B lymphoma cell lines. Deletion of either CD79 protein caused loss of surface IgM in all cell lines and reduced fitness in three. From two cell lines, we generated stable CD79A or CD79B knockout clones and demonstrated that loss of CD79A or CD79B caused a block in N-glycan maturation and accumulation of immature proteins, compatible with retention of BCR components in the endoplasmic reticulum. Rescue experiments with CD79B wild-type restored surface expression of CD79A and IgM with mature glycosylation, whereas a naturally occurring CD79B G137S mutant disrupting CD79A/CD79B heterodimerization did not. Our study highlights that CD79A and CD79B are required for surface IgM expression in human B cells and illuminates the importance of the IgM expression level for signaling and fitness., (Copyright © 2022 by The American Association of Immunologists, Inc.)
- Published
- 2022
- Full Text
- View/download PDF
23. A phase I/II escalation trial design T-RAD: Treatment of metastatic lung cancer with mRNA-engineered T cells expressing a T cell receptor targeting human telomerase reverse transcriptase (hTERT).
- Author
-
Maggadóttir SM, Kvalheim G, Wernhoff P, Sæbøe-Larssen S, Revheim ME, Josefsen D, Wälchli S, Helland Å, and Inderberg EM
- Abstract
Background: Adoptive cellular therapy (ACT) with genetically modified T cells aims to redirect T cells against resistant cancers through introduction of a T cell receptor (TCR). The Radium-4 TCR was isolated from a responding patient in a cancer vaccination study and recognizes the enzymatic component of human Telomerase Reverse Transcriptase (hTERT) presented on MHC class II (HLA-DP04). hTERT is a constitutively overexpressed tumor-associated antigen present in most human cancers, including non-small-cell lung cancer (NSCLC), which is the second most common type of cancer worldwide. Treatment alternatives for relapsing NSCLC are limited and survival is poor. To improve patient outcome we designed a TCR-based ACT study targeting hTERT., Methods: T-RAD is a phase I/II study to evaluate the safety and efficacy of Radium-4 mRNA electroporated autologous T cells in the treatment of metastatic NSCLC with no other treatment option. Transient TCR expression is applied for safety considerations. Participants receive two intravenous injections with escalating doses of redirected T cells weekly for 6 consecutive weeks. Primary objectives are safety and tolerability. Secondary objectives include progression-free survival, time to progression, overall survival, patient reported outcomes and overall radiological response., Discussion: Treatment for metastatic NSCLC is scarce and new personalized treatment options are in high demand. hTERT is a tumor target applicable to numerous cancer types. This proof-of-concept study will explore for the first time the safety and efficacy of TCR mRNA electroporated autologous T cells targeting hTERT. The T-RAD study will thus evaluate an attractive candidate for future immunotherapy of solid tumors., Competing Interests: The authors declare the following potential conflict of interest: GK, SW, and EI are named inventors on a patent on Radium-4 TCR WO2019166463. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Maggadóttir, Kvalheim, Wernhoff, Sæbøe-Larssen, Revheim, Josefsen, Wälchli, Helland and Inderberg.)
- Published
- 2022
- Full Text
- View/download PDF
24. How CAR T Cells Breathe.
- Author
-
Forcados C, Joaquina S, Casey NP, Caulier B, and Wälchli S
- Subjects
- Glycolysis, Humans, Immunotherapy, Adoptive methods, T-Lymphocytes metabolism, Tumor Microenvironment, Receptors, Chimeric Antigen metabolism
- Abstract
The manufacture of efficacious CAR T cells represents a major challenge in cellular therapy. An important aspect of their quality concerns energy production and consumption, known as metabolism. T cells tend to adopt diverse metabolic profiles depending on their differentiation state and their stimulation level. It is therefore expected that the introduction of a synthetic molecule such as CAR, activating endogenous signaling pathways, will affect metabolism. In addition, upon patient treatment, the tumor microenvironment might influence the CAR T cell metabolism by compromising the energy resources. The access to novel technology with higher throughput and reduced cost has led to an increased interest in studying metabolism. Indeed, methods to quantify glycolysis and mitochondrial respiration have been available for decades but were rarely applied in the context of CAR T cell therapy before the release of the Seahorse XF apparatus. The present review will focus on the use of this instrument in the context of studies describing the impact of CAR on T cell metabolism and the strategies to render of CAR T cells more metabolically fit.
- Published
- 2022
- Full Text
- View/download PDF
25. CAR-Ts: new perspectives in cancer therapy.
- Author
-
Abrantes R, Duarte HO, Gomes C, Wälchli S, and Reis CA
- Subjects
- Antigens, Neoplasm genetics, Binding Sites, Carbohydrate Sequence, Genetic Engineering methods, Glycosylation, Humans, Neoplasms genetics, Neoplasms immunology, Neoplasms pathology, Polysaccharides chemistry, Protein Binding, Protein Domains, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell immunology, Receptors, Chimeric Antigen genetics, T-Lymphocytes cytology, T-Lymphocytes transplantation, Tumor Microenvironment genetics, Tumor Microenvironment immunology, Antigens, Neoplasm immunology, Immunotherapy, Adoptive methods, Neoplasms therapy, Polysaccharides immunology, Receptors, Chimeric Antigen immunology, T-Lymphocytes immunology
- Abstract
Chimeric antigen receptor (CAR)-T-cell therapy is a promising anticancer treatment that exploits the host's immune system to fight cancer. CAR-T cell therapy relies on immune cells being modified to express an artificial receptor targeting cancer-specific markers, and infused into the patients where they will recognize and eliminate the tumour. Although CAR-T cell therapy has produced encouraging outcomes in patients with haematologic malignancies, solid tumours remain challenging to treat, mainly due to the lack of cancer-specific molecular targets and the hostile, often immunosuppressive, tumour microenvironment. CAR-T cell therapy also depends on the quality of the injected product, which is closely connected to CAR design. Here, we explain the technology of CAR-Ts, focusing on the composition of CARs, their application, and limitations in cancer therapy, as well as on the current strategies to overcome the challenges encountered. We also address potential future targets to overcome the flaws of CAR-T cell technology in the treatment of cancer, emphasizing glycan antigens, the aberrant forms of which attain high tumour-specific expression, as promising targets for CAR-T cell therapy., (© 2022 Federation of European Biochemical Societies.)
- Published
- 2022
- Full Text
- View/download PDF
26. In vivo experimental mouse model to test CD19CAR T cells generated with different methods.
- Author
-
Fåne A, Myhre MR, Inderberg EM, and Wälchli S
- Subjects
- Animals, Cell Line, Cell Line, Tumor, Immunotherapy, Adoptive methods, Mice, Receptors, Antigen, T-Cell metabolism, Neoplasms metabolism, T-Lymphocytes metabolism
- Abstract
Pre-clinical evaluation of CAR T cells includes procedures testing T-cell efficacy and safety in as close to real world conditions as possible. An important step in efficacy testing is the in vivo study, most often using immunodeficient murine models into which both the poison and the cure are injected; namely a human cancer cell line and genetically modified human T cells. The capacity of the T cells to control the cancer progression will provide information about the CAR T-cell efficacy. We here provide a protocol to test CAR T cells in vivo using the validated anti-B-cell marker CD19CAR and an aggressive lymphoma model., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
27. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells.
- Author
-
Bajor M, Graczyk-Jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A, Zhylko A, Soroczynska K, Retecki K, Krawczyk M, Klopotowska M, Pilch Z, Paczek L, Malmberg KJ, Wälchli S, Winiarska M, and Zagozdzon R
- Subjects
- Animals, B7-H1 Antigen analysis, B7-H1 Antigen antagonists & inhibitors, Cell Line, Tumor, Female, HEK293 Cells, Humans, Mice, Receptor, ErbB-2 antagonists & inhibitors, Xenograft Model Antitumor Assays, Breast Neoplasms therapy, Cytotoxicity, Immunologic, Immune Checkpoint Inhibitors therapeutic use, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen immunology
- Abstract
Background: Immune checkpoint inhibitors and chimeric antigen receptor (CAR)-based therapies have transformed cancer treatment. Recently, combining these approaches into a strategy of PD-L1-targeted CAR has been proposed to target PD-L1
high tumors. Our study provides new information on the efficacy of such an approach against PD-L1low targets., Methods: New atezolizumab-based PD-L1-targeted CAR was generated and introduced into T, NK, or NK-92 cells. Breast cancer MDA-MB-231 and MCF-7 cell lines or non-malignant cells (HEK293T, HMEC, MCF-10A, or BM-MSC) were used as targets to assess the reactivity or cytotoxic activity of the PD-L1-CAR-bearing immune effector cells. Stimulation with IFNγ or with supernatants from activated CAR T cells were used to induce upregulation of PD-L1 molecule expression on the target cells. HER2-CAR T cells were used for combination with PD-L1-CAR T cells against MCF-7 cells., Results: PD-L1-CAR effector cells responded vigorously with degranulation and cytokine production to PD-L1high MDA-MB-231 cells, but not to PD-L1low MCF-7 cells. However, in long-term killing assays, both MDA-MB-231 and MCF-7 cells were eliminated by the PD-L1-CAR cells, although with a delay in the case of PD-L1low MCF-7 cells. Notably, the coculture of MCF-7 cells with activated PD-L1-CAR cells led to bystander induction of PD-L1 expression on MCF-7 cells and to the unique self-amplifying effect of the PD-L1-CAR cells. Accordingly, PD-L1-CAR T cells were active not only against MDA-MD-231 and MCF-7-PD-L1 but also against MCF-7-pLVX cells in tumor xenograft models. Importantly, we have also observed potent cytotoxic effects of PD-L1-CAR cells against non-malignant MCF-10A, HMEC, and BM-MSC cells, but not against HEK293T cells that initially did not express PD-L1 and were unresponsive to the stimulation . Finally, we have observed that HER-2-CAR T cells stimulate PD-L1 expression on MCF-7 cells and therefore accelerate the functionality of PD-L1-CAR T cells when used in combination., Conclusions: In summary, our studies show that CAR-effector cells trigger the expression of PD-L1 on target cells, which in case of PD-L1-CAR results in the unique self-amplification phenomenon. This self-amplifying effect could be responsible for the enhanced cytotoxicity of PD-L1-CAR T cells against both malignant and non-malignant cells and implies extensive caution in introducing PD-L1-CAR strategy into clinical studies., Competing Interests: Competing interests: K-JM is a consultant at Fate Therapeutics and a member of the SAB at Vycellix., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.)- Published
- 2022
- Full Text
- View/download PDF
28. Rab7b regulates dendritic cell migration by linking lysosomes to the actomyosin cytoskeleton.
- Author
-
Vestre K, Persiconi I, Borg Distefano M, Mensali N, Guadagno NA, Bretou M, Wälchli S, Arnold-Schrauf C, Bakke O, Dalod M, Lennon-Dumenil AM, and Progida C
- Subjects
- Cytoskeleton, Dendritic Cells, Endosomes, Humans, Actomyosin, Lysosomes
- Abstract
Lysosomal signaling facilitates the migration of immune cells by releasing Ca2+ to activate the actin-based motor myosin II at the cell rear. However, how the actomyosin cytoskeleton physically associates to lysosomes is unknown. We have previously identified myosin II as a direct interactor of Rab7b, a small GTPase that mediates the transport from late endosomes/lysosomes to the trans-Golgi network (TGN). Here, we show that Rab7b regulates the migration of dendritic cells (DCs) in one- and three-dimensional environments. DCs are immune sentinels that transport antigens from peripheral tissues to lymph nodes to activate T lymphocytes and initiate adaptive immune responses. We found that the lack of Rab7b reduces myosin II light chain phosphorylation and the activation of the transcription factor EB (TFEB), which controls lysosomal signaling and is required for fast DC migration. Furthermore, we demonstrate that Rab7b interacts with the lysosomal Ca2+ channel TRPML1 (also known as MCOLN1), enabling the local activation of myosin II at the cell rear. Taken together, our findings identify Rab7b as the missing physical link between lysosomes and the actomyosin cytoskeleton, allowing control of immune cell migration through lysosomal signaling. This article has an associated First Person interview with the first author of the paper., Competing Interests: Competing interests The authors declare no competing or financial interests., (© 2021. Published by The Company of Biologists Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
29. "Built-in" PD-1 blocker to rescue NK-92 activity from PD-L1-mediated tumor escape mechanisms.
- Author
-
Mensali N, Dillard P, Fayzullin A, Köksal H, Gaudernack G, Kvalheim G, Inderberg EM, and Wälchli S
- Subjects
- Animals, Cell Adhesion, Cell Engineering, Cell Line, Tumor, Cell Survival, Genetic Engineering, Humans, Mice, Neoplasms pathology, Programmed Cell Death 1 Receptor metabolism, RNA, Messenger genetics, Xenograft Model Antitumor Assays, B7-H1 Antigen immunology, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Neoplasms immunology, Programmed Cell Death 1 Receptor antagonists & inhibitors, Tumor Escape immunology
- Abstract
Success of adoptive cell therapy mainly depends on the ability of immune cells to persist and function optimally in the immunosuppressive tumor microenvironment. Although present at the cancer site, immune cells become exhausted and/or inhibited, due to the presence of inhibitory receptors such as PD-L1 on malignant cells. Novel genetic strategies to manipulate the PD1/PD-L1 axis comprise (i) PD-1 reversion where the receptor intracellular domain is replaced with an activating unit, (ii) the use of anti-PD-L1 CAR or (iii) the disruption of the PD-1 gene. We here present an alternative strategy to equip therapeutic cells with a truncated PD-1 (tPD-1) to abrogate PD-1/PD-L1 inhibition. We show that engagement of tPD-1 with PD-L1-positive tumor unleashes NK-92 activity in vitro. Furthermore, this binding was sufficiently strong to induce killing of targets otherwise not recognized by NK-92, thus increasing the range of targets. In vivo treatment with NK-92 tPD-1 cells led to reduced tumor growth and improved survival. Importantly, tPD-1 did not interfere with tumor recognition in PD-L1 negative conditions. Thus, tPD-1 represents a straightforward method for improving antitumor immunity and revealing new targets through PD-L1 positivity., (© 2021 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology.)
- Published
- 2021
- Full Text
- View/download PDF
30. Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.
- Author
-
Dillard P, Casey N, Pollmann S, Vernhoff P, Gaudernack G, Kvalheim G, Wälchli S, and Inderberg EM
- Subjects
- Antigens, Neoplasm, HLA Antigens, Humans, Mutation, Receptors, Antigen, T-Cell genetics, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras) genetics
- Abstract
T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isolated four KRAS-specific TCRs from a long-term surviving pancreatic cancer patient vaccinated with a mix of mutated KRAS peptides. The sequence of these TCRs could be identified and expressed in primary cells. We demonstrated stable expression of all TCRs as well as target-specific functionality when expressing T cells were co-incubated with target cells presenting KRAS peptides. In addition, these TCRs were all partially co-receptor independent since they were functional in both CD4 and CD8 T cells, thus indicating high affinity. Interestingly, we observed that certain TCRs were able to recognize several KRAS mutations in complex with their cognate Human leukocyte antigen (HLA), suggesting that, here, the point mutations were less important for the HLA binding and TCR recognition, whereas others were single-mutation restricted. Finally, we demonstrated that these peptides were indeed processed and presented, since HLA-matched antigen presenting cells exogenously loaded with KRAS proteins were recognized by TCR-transduced T cells. Taken together, our data demonstrate that KRAS mutations are immunogenic for CD4 T cells and are interesting targets for TCR-based cancer immunotherapy., (© 2021 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Published
- 2021
- Full Text
- View/download PDF
31. Pharmacologic Control of CAR T Cells.
- Author
-
Caulier B, Enserink JM, and Wälchli S
- Subjects
- B-Lymphocytes, Humans, Neoplasms immunology, Immunotherapy, Adoptive, Neoplasms therapy
- Abstract
Chimeric antigen receptor (CAR) therapy is a promising modality for the treatment of advanced cancers that are otherwise incurable. During the last decade, different centers worldwide have tested the anti-CD19 CAR T cells and shown clinical benefits in the treatment of B cell tumors. However, despite these encouraging results, CAR treatment has also been found to lead to serious side effects and capricious response profiles in patients. In addition, the CD19 CAR success has been difficult to reproduce for other types of malignancy. The appearance of resistant tumor variants, the lack of antigen specificity, and the occurrence of severe adverse effects due to over-stimulation of the therapeutic cells have been identified as the major impediments. This has motivated a growing interest in developing strategies to overcome these hurdles through CAR control. Among them, the combination of small molecules and approved drugs with CAR T cells has been investigated. These have been exploited to induce a synergistic anti-cancer effect but also to control the presence of the CAR T cells or tune the therapeutic activity. In the present review, we discuss opportunistic and rational approaches involving drugs featuring anti-cancer efficacy and CAR-adjustable effect.
- Published
- 2021
- Full Text
- View/download PDF
32. Id2 Represses Aldosterone-Stimulated Cardiac T-Type Calcium Channels Expression.
- Author
-
Ito J, Minemura T, Wälchli S, Niimi T, Fujihara Y, Kuroda S, Takimoto K, and Maturana AD
- Subjects
- Animals, Calcium Channels, T-Type genetics, Cells, Cultured, Gene Expression Regulation drug effects, Heart drug effects, Heart physiology, Inhibitor of Differentiation Protein 2 genetics, Mice, Transgenic, Myocytes, Cardiac drug effects, Aldosterone pharmacology, Calcium Channels, T-Type metabolism, Inhibitor of Differentiation Protein 2 metabolism, Myocytes, Cardiac metabolism
- Abstract
Aldosterone excess is a cardiovascular risk factor. Aldosterone can directly stimulate an electrical remodeling of cardiomyocytes leading to cardiac arrhythmia and hypertrophy. L-type and T-type voltage-gated calcium (Ca
2+ ) channels expression are increased by aldosterone in cardiomyocytes. To further understand the regulation of these channels expression, we studied the role of a transcriptional repressor, the inhibitor of differentiation/DNA binding protein 2 (Id2). We found that aldosterone inhibited the expression of Id2 in neonatal rat cardiomyocytes and in the heart of adult mice. When Id2 was overexpressed in cardiomyocytes, we observed a reduction in the spontaneous action potentials rate and an arrest in aldosterone-stimulated rate increase. Accordingly, Id2 siRNA knockdown increased this rate. We also observed that CaV1.2 (L-type Ca2+ channel) or CaV3.1, and CaV3.2 (T-type Ca2+ channels) mRNA expression levels and Ca2+ currents were affected by Id2 presence. These observations were further corroborated in a heart specific Id2- transgenic mice. Taken together, our results suggest that Id2 functions as a transcriptional repressor for L- and T-type Ca2+ channels, particularly CaV3.1, in cardiomyocytes and its expression is controlled by aldosterone. We propose that Id2 might contributes to a protective mechanism in cardiomyocytes preventing the presence of channels associated with a pathological state.- Published
- 2021
- Full Text
- View/download PDF
33. Targeting Telomerase with an HLA Class II-Restricted TCR for Cancer Immunotherapy.
- Author
-
Dillard P, Köksal H, Maggadottir SM, Winge-Main A, Pollmann S, Menard M, Myhre MR, Mælandsmo GM, Flørenes VA, Gaudernack G, Kvalheim G, Wälchli S, and Inderberg EM
- Subjects
- Animals, Apoptosis, Cell Proliferation, Humans, Melanoma immunology, Melanoma metabolism, Melanoma pathology, Mice, Mice, Inbred NOD, Mice, SCID, Tumor Cells, Cultured, Xenograft Model Antitumor Assays, CD8-Positive T-Lymphocytes immunology, Histocompatibility Antigens Class II immunology, Immunotherapy methods, Melanoma therapy, Receptors, Antigen, T-Cell immunology, T-Lymphocytes, Cytotoxic immunology, Telomerase antagonists & inhibitors
- Abstract
T cell receptor (TCR)-engineered T cell therapy is a promising cancer treatment approach. Human telomerase reverse transcriptase (hTERT) is overexpressed in the majority of tumors and a potential target for adoptive cell therapy. We isolated a novel hTERT-specific TCR sequence, named Radium-4, from a clinically responding pancreatic cancer patient vaccinated with a long hTERT peptide. Radium-4 TCR-redirected primary CD4
+ and CD8+ T cells demonstrated in vitro efficacy, producing inflammatory cytokines and killing hTERT+ melanoma cells in both 2D and 3D settings, as well as malignant, patient-derived ascites cells. Importantly, T cells expressing Radium-4 TCR displayed no toxicity against bone marrow stem cells or mature hematopoietic cells. Notably, Radium-4 TCR+ T cells also significantly reduced tumor growth and improved survival in a xenograft mouse model. Since hTERT is a universal cancer antigen, and the very frequently expressed HLA class II molecules presenting the hTERT peptide to this TCR provide a very high (>75%) population coverage, this TCR represents an attractive candidate for immunotherapy of solid tumors., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
34. Combinatorial CAR design improves target restriction.
- Author
-
Köksal H, Dillard P, Juzeniene A, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, and Wälchli S
- Subjects
- Antigens, CD19 metabolism, B-Lymphocytes metabolism, CD28 Antigens metabolism, Cell Line, Tumor, Humans, Immunotherapy, Adoptive, Lymphoma metabolism, Receptors, Chimeric Antigen chemistry, T-Lymphocytes metabolism, Receptors, Antigen, T-Cell metabolism, Receptors, Chimeric Antigen metabolism
- Abstract
CAR T cells targeting the B lymphocyte antigen CD19 have led to remarkable clinical results in B cell leukemia and lymphoma but eliminate all B lineage cells, leading to increased susceptibility to severe infections. As malignant B cells will express either immunoglobulin (Ig) light chain κ or λ, we designed a second-generation CAR targeting Igκ, IGK CAR. This construct demonstrated high target specificity but displayed reduced efficacy in the presence of serum IgG. Since CD19 CAR is insensitive to serum IgG, we designed various combinatorial CAR constructs in order to maintain the CD19 CAR T cell efficacy, but with IGK CAR target selectivity. The Kz-19BB design, combining CD19 CAR containing a 4-1BB costimulatory domain with an IGK CAR containing a CD3zeta stimulatory domain, maintained the target specificity of IgK CAR and was resistant to the presence of soluble IgG. Our results demonstrate that a combinatorial CAR approach can improve target selectivity and efficacy., Competing Interests: Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
35. T cell receptor therapy against melanoma-Immunotherapy for the future?
- Author
-
Winge-Main AK, Wälchli S, and Inderberg EM
- Subjects
- Animals, Humans, Melanoma, Cutaneous Malignant, Immunotherapy methods, Melanoma immunology, Melanoma therapy, Receptors, Antigen, T-Cell immunology, Skin Neoplasms immunology, Skin Neoplasms therapy
- Abstract
Malignant melanoma has seen monumental changes in treatment options the last decade from the very poor results of dacarbazine treatment to the modern-day use of targeted therapies and immune checkpoint inhibitors. Melanoma has a high mutational burden making it more capable of evoking immune responses than many other tumours. Even when considering double immune checkpoint blockade with anti-CTLA-4 and anti-PD-1, we still have far to go in melanoma treatment as 50% of patients with metastatic disease do not respond to current treatment. Alternative immunotherapy should therefore be considered. Since melanoma has a high mutational burden, it is considered more immunogenic than many other tumours. T cell receptor (TCR) therapy could be a possible way forward, either alone or in combination, to improve the response rates of this deadly disease. Melanoma is one of the cancers where TCR therapy has been frequently applied. However, the number of antigens targeted remains fairly limited, although advanced personalized therapies aim at also targeting private mutations. In this review, we look at possible aspects of targeting TCR therapy towards melanoma and provide an implication of its use in the future., (© 2020 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.)
- Published
- 2020
- Full Text
- View/download PDF
36. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy.
- Author
-
Benard E, Casey NP, Inderberg EM, and Wälchli S
- Subjects
- Animals, Antigens, Neoplasm immunology, Carcinoma, Ovarian Epithelial therapy, Female, Humans, Immunotherapy, Adoptive methods, Ovarian Neoplasms therapy, Receptors, Chimeric Antigen therapeutic use, Tumor Escape immunology, Carcinoma, Ovarian Epithelial immunology, Ovarian Neoplasms immunology, Receptors, Chimeric Antigen immunology, Tumor Microenvironment immunology
- Abstract
Ovarian Cancer (OC) is currently difficult to cure, mainly due to its late detection and the advanced state of the disease at the time of diagnosis. Therefore, conventional treatments such as debulking surgery and combination chemotherapy are rarely able to control progression of the tumour, and relapses are frequent. Alternative therapies are currently being evaluated, including immunotherapy and advanced T cell-based therapy. In the present review, we will focus on a description of those Chimeric Antigen Receptors (CARs) that have been validated in the laboratory or are being tested in the clinic. Numerous target antigens have been defined due to the identification of OC biomarkers, and many are being used as CAR targets. We provide an exhaustive list of these constructs and their current status. Despite being innovative and efficient, the OC-specific CARs face a barrier to their clinical efficacy: the tumour microenvironment (TME). Indeed, effector cells expressing CARs have been shown to be severely inhibited, rendering the CAR T cells useless once at the tumour site. Herein, we give a thorough description of the highly immunosuppressive OC TME and present recent studies and innovations that have enabled CAR T cells to counteract this negative environment and to destroy tumours., (© 2020 The Authors. Scandinavian Journal of Immunology published by John Wiley & Sons Ltd on behalf of The Scandinavian Foundation for Immunology.)
- Published
- 2020
- Full Text
- View/download PDF
37. Sympathetic improvement of cancer vaccine efficacy.
- Author
-
Inderberg EM and Wälchli S
- Subjects
- CD8-Positive T-Lymphocytes, Humans, Immunotherapy, Neoplasm Recurrence, Local, Signal Transduction, Cancer Vaccines
- Abstract
The link between stress, other psychological factors and response to cancer, or even the cancer incidence and metastasis, is well established. The inhibition of β-Adrenergic receptors (β-AR) using β-blockers was demonstrated to have an inhibitory effect on cancer recurrence. Direct effects on the stress-induced suppression of anti-tumor immune responses were also shown. In a recent issue of Cancer Immunology Research, Daher and colleagues studied the molecular mechanism behind this protective effect in the context of cancer vaccination. They provided evidence that the β-AR signaling affected the priming of naïve CD8 + T cells in their myeloma model, rather than effector CD8 + T cells which downregulated the expression of β-AR after activation and became insensitive to such signaling. Blocking the β-adrenergic signaling during vaccination led to increased expansion and effector functions of antigen-specific CD8 + T cells and reduced tumor growth. This has implications for the clinical use of β-blockers as adjuvants to enhance cancer vaccination and other types of immunotherapy.
- Published
- 2020
- Full Text
- View/download PDF
38. Colorectal cysts as a validating tool for CAR therapy.
- Author
-
Dillard P, Lie M, Baken E, Lobert VH, Benard E, Köksal H, Inderberg EM, and Wälchli S
- Subjects
- B-Lymphocytes metabolism, Caco-2 Cells, Cysts, Heterografts, Humans, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell metabolism, Receptors, Chimeric Antigen, T-Lymphocytes immunology, Tumor Microenvironment, Colorectal Neoplasms therapy, Immunotherapy methods, Immunotherapy, Adoptive methods
- Abstract
Background: Treatment of cancers has largely benefited from the development of immunotherapy. In particular, Chimeric Antigen Receptor (CAR) redirected T cells have demonstrated impressive efficacy against B-cell malignancies and continuous efforts are made to adapt this new therapy to solid tumors, where the immunosuppressive tumor microenvironment is a barrier for delivery. CAR T-cell validation relies on in vitro functional assays using monolayer or suspension cells and in vivo xenograft models in immunodeficient animals. However, the efficacy of CAR therapies remains difficult to predict with these systems, in particular when challenged against 3D organized solid tumors with highly intricate microenvironment. An increasing number of reports have now included an additional step in the development process in which redirected T cells are tested against tumor spheres., Results: Here, we report a method to produce 3D structures, or cysts, out of a colorectal cancer cell line, Caco-2, which has the ability to form polarized spheroids as a validation tool for adoptive cell therapy in general. We used CD19CAR T cells to explore this method and we show that it can be adapted to various platforms including high resolution microscopy, bioluminescence assays and high-throughput live cell imaging systems., Conclusion: We developed an affordable, reliable and practical method to produce cysts to validate therapeutic CAR T cells. The integration of this additional layer between in vitro and in vivo studies could be an important tool in the pre-clinical workflow of cell-based immunotherapy.
- Published
- 2020
- Full Text
- View/download PDF
39. Long-term surviving cancer patients as a source of therapeutic TCR.
- Author
-
Inderberg EM and Wälchli S
- Subjects
- CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism, Cancer Vaccines administration & dosage, Clinical Trials as Topic, Histocompatibility Antigens Class II immunology, Humans, Immunotherapy, Adoptive trends, Neoplasms blood, Neoplasms immunology, Receptors, Antigen, T-Cell immunology, Receptors, Antigen, T-Cell metabolism, CD4-Positive T-Lymphocytes transplantation, Cancer Survivors, Immunotherapy, Adoptive methods, Neoplasms therapy, Receptors, Antigen, T-Cell isolation & purification
- Abstract
We have established a platform for the isolation of tumour-specific TCR from T cells of patients who experienced clinical benefit from cancer vaccination. In this review we will present the rationale behind this strategy and discuss the advantages of working with "natural" wild type TCRs. Indeed, the general trend in the field has been to use various modifications to enhance the affinity of such therapeutic TCRs. This was done to obtain stronger T cell responses, often at the cost of safety. We further describe antigen targets and recent in vitro and in vivo results obtained to validate them. We finally discuss the use of MHC class II-restricted TCR in immunotherapy. Typically cellular anti-tumour immune responses have been attributed to CD8 T cells; however, we isolated mainly CD4 T cells. Importantly, these MHC class II-restricted TCRs have the potential to induce broad, long lasting immune responses that enable cancer control. The use of CD4 T cell-derived TCRs for adoptive immunotherapy has so far been limited and we will here discuss their therapeutic potential.
- Published
- 2020
- Full Text
- View/download PDF
40. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
- Author
-
Bai B, Myklebust JH, and Wälchli S
- Subjects
- B-Lymphocytes metabolism, CRISPR-Associated Protein 9 genetics, Cell Line, Tumor, Clustered Regularly Interspaced Short Palindromic Repeats, Electroporation methods, Gene Transfer Techniques, Humans, Lymphoma, B-Cell therapy, RNA, Guide, CRISPR-Cas Systems genetics, Transduction, Genetic methods, CRISPR-Cas Systems, Gene Editing methods, Lymphoma, B-Cell genetics
- Abstract
Genome editing in eukaryotes has greatly improved through the application of targeted editing tools. The development of the CRISPR/Cas9 technology has facilitated genome editing in mammalian cells. However, efficient delivery of CRISPR components into cells growing in suspension remains a challenge. Here, we present a strategy for sequential delivery of the two essential components, Cas9 and sgRNA, into B-lymphoid cell lines. Stable Cas9 expression is obtained by retroviral transduction, before sgRNA is transiently delivered into the Cas9+ cells. This method improves the on-target efficiency of genome editing and, through the transient presence of sgRNA, reduces the potential off-target sites. The current method can be easily applied to other cell types that are difficult to edit with CRISPR/Cas9.
- Published
- 2020
- Full Text
- View/download PDF
41. Next Generation of Adoptive T Cell Therapy Using CRISPR/Cas9 Technology: Universal or Boosted?
- Author
-
Wälchli S and Sioud M
- Subjects
- Animals, Humans, Immunotherapy, Adoptive adverse effects, T-Lymphocytes metabolism, T-Lymphocytes transplantation, CRISPR-Cas Systems, Gene Editing methods, Immunotherapy, Adoptive methods
- Abstract
Adoptive T cell therapy (ACT) using either chimeric antigen receptor (CAR)- or T cell receptor (TCR)-engineered lymphocytes has emerged as a promising strategy to treat cancer. However, this therapy is still facing enormous challenges such as poor quality of autologous T cells, T cell exhaustion, and the immune suppressive tumor microenvironments. Additionally, graft-versus-host disease is an issue that must be addressed to allow the use of allogeneic T cells. Strategies to overcome these therapeutic challenges using gene editing technology are now being developed. One strategy is to disrupt TCR and/or MHC expression in healthy donor T cells to generate T cells for universal use. Another strategy is to improve the quality of patient's T cells by eliminating either the expression of selected immune checkpoint receptors or negative regulators of TCR signaling and/or T-cell homeostasis. Here, we review the use of CRISPR-Cas9 platform in T cell engineering with a focus on the development of universal T cells and boosted autologous cells for next-generation ACT.
- Published
- 2020
- Full Text
- View/download PDF
42. Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
- Author
-
Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, and Inderberg EM
- Abstract
The original version of this article unfortunately included a mistake in Fig. 2b where the images of mice in the tumour control group (right), day 30 (bottom) should be removed as the wrong images (duplicate of day 17) were inserted by mistake. At this time point the tumour control mice were no longer alive and the images were replaced by black areas.
- Published
- 2020
- Full Text
- View/download PDF
43. Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy.
- Author
-
Mensali N, Myhre MR, Dillard P, Pollmann S, Gaudernack G, Kvalheim G, Wälchli S, and Inderberg EM
- Subjects
- Animals, Colorectal Neoplasms immunology, Cross Reactions, Cytotoxicity, Immunologic, Electroporation, HCT116 Cells, Humans, Mice, Mice, SCID, Neoplasms, Experimental, RNA, Messenger genetics, Receptors, Chimeric Antigen genetics, T-Cell Antigen Receptor Specificity, T-Lymphocytes transplantation, Xenograft Model Antitumor Assays, Cancer Vaccines immunology, Colorectal Neoplasms therapy, Immunotherapy, Adoptive methods, Receptors, Chimeric Antigen metabolism, T-Lymphocytes immunology
- Abstract
Off-target toxicity due to the expression of target antigens in normal tissue or TCR cross-reactivity represents a major risk when using T cell receptor (TCR)-engineered T cells for treatment of solid tumours. Due to the inherent cross-reactivity of TCRs it is difficult to accurately predict their target recognition pre-clinically. It has become evident that direct testing in a human being represents the best evaluation of the risks. There is, therefore, a clear unmet need for assessing the safety of a therapeutic TCR in a more controllable manner than by the injection of permanently modified cellular products. Using transiently modified T cells combined with dose escalation has already been shown feasible for chimeric antigen receptor (CAR)-engineered T cells, but nothing is yet reported for TCR. We performed a preclinical evaluation of a therapeutic TCR transiently expressed in T cells by mRNA electroporation. We analyzed if the construct was active in vitro, how long it was detectable for and if this expression format was adapted to in vivo efficacy assessment. Our data demonstrate the potential of mRNA engineered T cells, although less powerful than permanent redirection, to induce a significant response. Thus, these findings support the development of mRNA based TCR-therapy strategies as a feasible and efficacious method for evaluating TCR safety and efficacy in first-in-man testing.
- Published
- 2019
- Full Text
- View/download PDF
44. Chimeric antigen receptor preparation from hybridoma to T-cell expression.
- Author
-
Köksal H, Baken E, Warren DJ, Løset GÅ, Inderberg EM, and Wälchli S
- Abstract
The successful use of chimeric antigen receptor (CAR) for hematological cancer treatment has influenced the direction taken in translational research toward an increasing focus on personalized targeted immunotherapy. Thus, a growing number of labs worldwide are now interested in testing their old antibody collections in this format to broaden the spectrum of utility and improve safety and efficacy. We herein present a straightforward protocol for the identification of an antibody from a hybridoma and the design of the single chain fragment that will be placed on the extracellular part of the CAR construct. We further show how to test the expression and the activity of the construct in primary T cells. We illustrate our demonstration with two new CARs targeted against the B cell receptor, more precisely the light chains κ and λ, that represent potential alternatives to the CD19 CAR used in the treatment of B-cell malignancies., (© The Author(s) 2019. Published by Oxford University Press on behalf of Antibody Therapeutics.)
- Published
- 2019
- Full Text
- View/download PDF
45. Preclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphoma.
- Author
-
Köksal H, Dillard P, Josefsson SE, Maggadottir SM, Pollmann S, Fåne A, Blaker YN, Beiske K, Huse K, Kolstad A, Holte H, Kvalheim G, Smeland EB, Myklebust JH, Inderberg EM, and Wälchli S
- Subjects
- Animals, Antigens, CD19 immunology, Humans, Jurkat Cells, K562 Cells, Mice, Mice, Inbred NOD, Mice, SCID, Xenograft Model Antitumor Assays, Adoptive Transfer, Antigens, Neoplasm immunology, Lymphoma, B-Cell immunology, Lymphoma, B-Cell pathology, Lymphoma, B-Cell therapy, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma immunology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma pathology, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma therapy, Receptors, Chimeric Antigen immunology, Tetraspanins immunology
- Abstract
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. CD19CAR T-cell therapy has also demonstrated prominent effects in B-cell non-Hodgkin lymphoma (B-NHL) patients. However, a subset of patients who relapse after CD19CAR T-cell therapy have outgrowth of CD19
- tumor cells. Hence, development of alternative CARs targeting other B-cell markers represents an unmet medical need for B-cell acute lymphoblastic leukemia and B-NHL. Here, we confirmed previous data by showing that, overall, B-NHL has high expression of CD37. A second-generation CD37CAR was designed, and its efficacy in T cells was compared with that of CD19CAR. In vitro assessment of cytotoxicity and T-cell function upon coculture of the CAR T cells with different target B-cell lymphoma cell lines demonstrated comparable efficacy between the 2 CARs. In an aggressive B-cell lymphoma xenograft model, CD37CAR T cells were as potent as CD19CAR T cells in controlling tumor growth. In a second xenograft model, using U2932 lymphoma cells containing a CD19- subpopulation, CD37CAR T cells efficiently controlled tumor growth and prolonged survival, whereas CD19CAR T cells had limited effect. We further show that, unlike CD19CAR, CD37CAR was not sensitive to antigen masking. Finally, CD37CAR reactivity was restricted to B-lineage cells. Collectively, our results demonstrated that CD37CAR T cells also can effectively eradicate B-cell lymphoma tumors when CD19 antigen expression is lost and support further clinical testing for patients with relapsed/refractory B-NHL., (© 2019 by The American Society of Hematology.)- Published
- 2019
- Full Text
- View/download PDF
46. Simultaneous defeat of MCF7 and MDA-MB-231 resistances by a hypericin PDT-tamoxifen hybrid therapy.
- Author
-
Theodossiou TA, Ali M, Grigalavicius M, Grallert B, Dillard P, Schink KO, Olsen CE, Wälchli S, Inderberg EM, Kubin A, Peng Q, and Berg K
- Abstract
Currently the greatest challenge in oncology is the lack of homogeneity of the lesions where different cell components respond differently to treatment. There is growing consensus that monotherapies are insufficient to eradicate the disease and there is an unmet need for more potent combinatorial treatments. We have previously shown that hypericin photodynamic therapy (HYP-PDT) triggers electron transport chain (ETC) inhibition in cell mitochondria. We have also shown that tamoxifen (TAM) enhances cytotoxicity in cells with high respiration, when combined with ETC inhibitors. Herein we introduce a synergistic treatment based on TAM chemotherapy and HYP-PDT. We tested this novel combinatorial treatment (HYPERTAM) in two metabolically different breast cancer cell lines, the triple-negative MDA-MB-231 and the estrogen-receptor-positive MCF7, the former being quite sensitive to HYP-PDT while the latter very responsive to TAM treatment. In addition, we investigated the mode of death, effect of lipid peroxidation, and the effect on cell metabolism. The results were quite astounding. HYPERTAM exhibited over 90% cytotoxicity in both cell lines. This cytotoxicity was in the form of both necrosis and autophagy, while high levels of lipid peroxidation were observed in both cell lines. We, consequently, translated our research to an in vivo pilot study encompassing the MDA-MB-231 and MCF7 tumor models in NOD SCID-γ immunocompromised mice. Both treatment cohorts responded very positively to HYPERTRAM, which significantly prolonged mice survival. HYPERTAM is a potent, synergistic modality, which may lay the foundations for a novel, composite anticancer treatment, effective in diverse tumor types., Competing Interests: The authors declare no competing interests.
- Published
- 2019
- Full Text
- View/download PDF
47. Treating osteosarcoma with CAR T cells.
- Author
-
Köksal H, Müller E, Inderberg EM, Bruland Ø, and Wälchli S
- Subjects
- Bone Neoplasms immunology, Bone Neoplasms mortality, Cancer-Associated Fibroblasts physiology, Endopeptidases, Gangliosides antagonists & inhibitors, Gelatinases physiology, Humans, Membrane Proteins physiology, Osteosarcoma immunology, Osteosarcoma mortality, Receptor, ErbB-2 analysis, Receptor, IGF Type 1 physiology, Receptors, Interleukin-11 antagonists & inhibitors, Serine Endopeptidases physiology, Tumor Microenvironment, Bone Neoplasms therapy, Immunotherapy, Adoptive methods, Osteosarcoma therapy
- Abstract
Novel therapies to treat patients with solid cancers that have developed resistance to chemotherapy represent unmet needs of considerable dimensions. In the present review, we will address the attempts to develop chimeric antigen receptor (CAR) targeted immunotherapy against osteosarcoma (OS). This aggressive cancer displays its peak incidence in children and young adults. The main cause of patient death is lung metastases with a 5-year survival as low as 5%-10% in the primary metastatic setting and 30% in the relapse situation, respectively. Effective adjuvant combination chemotherapy introduced more than 40 years ago improved the survival rates from below 20% to around 60% in patients; however, since then, no major breakthroughs have been made. The use of immune checkpoint inhibitors has been disappointing in OS, while other types of immunotherapies such as CAR T cells remain largely unexplored. Indeed, for CAR T-cell therapy to be efficacious, two main criteria need to be fulfilled: (a) CAR T cells should target an epitope selectively expressed on the cell surface of OS in order to prevent toxicities in normal tissues and (b) the target should also be widely expressed on OS metastases. These challenges have already been undertaken in OS and illustrate the difficulties in developing tomorrow's CAR-T treatment in a solid tumour. We will discuss the experiences with CAR-T therapy development and efficacy to combat the clinical challenges in OS., (© 2018 The Foundation for the Scandinavian Journal of Immunology.)
- Published
- 2019
- Full Text
- View/download PDF
48. TIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin Lymphoma.
- Author
-
Josefsson SE, Beiske K, Blaker YN, Førsund MS, Holte H, Østenstad B, Kimby E, Köksal H, Wälchli S, Bai B, Smeland EB, Levy R, Kolstad A, Huse K, and Myklebust JH
- Subjects
- Adult, Aged, Aged, 80 and over, Cell Line, Tumor, Cytokines metabolism, Female, Humans, Immunologic Memory, Ligands, Lymphoma, Non-Hodgkin metabolism, Middle Aged, Tumor Microenvironment, Lymphoma, Non-Hodgkin pathology, Programmed Cell Death 1 Receptor metabolism, Receptors, Immunologic metabolism, T-Lymphocyte Subsets metabolism
- Abstract
Checkpoint blockade can reverse T-cell exhaustion and promote antitumor responses. Although blocking the PD-1 pathway has been successful in Hodgkin lymphoma, response rates have been modest in B-cell non-Hodgkin lymphoma (NHL). Coblockade of checkpoint receptors may therefore be necessary to optimize antitumor T-cell responses. Here, characterization of coinhibitory receptor expression in intratumoral T cells from different NHL types identified TIGIT and PD-1 as frequently expressed coinhibitory receptors. Tumors from NHL patients were enriched in CD8
+ and CD4+ T effector memory cells that displayed high coexpression of TIGIT and PD-1, and coexpression of these checkpoint receptors identified T cells with reduced production of IFNγ, TNFα, and IL2. The suppressed cytokine production could be improved upon in vitro culture in the absence of ligands. Whereas PD-L1 was expressed by macrophages, the TIGIT ligands CD155 and CD112 were expressed by lymphoma cells in 39% and 50% of DLBCL cases and in some mantle cell lymphoma cases, as well as by endothelium and follicular dendritic cells in all NHLs investigated. Collectively, our results show that TIGIT and PD-1 mark dysfunctional T cells and suggest that TIGIT and PD-1 coblockade should be further explored to elicit potent antitumor responses in patients with NHL., (©2019 American Association for Cancer Research.)- Published
- 2019
- Full Text
- View/download PDF
49. NK cells specifically TCR-dressed to kill cancer cells.
- Author
-
Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fåne A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, and Wälchli S
- Subjects
- Animals, Biomarkers, Cell Line, Tumor, Cell Respiration, Disease Models, Animal, Energy Metabolism, Gene Expression Profiling, Humans, Immunophenotyping, Mice, Mitochondria metabolism, Neoplasms pathology, Neoplasms therapy, Signal Transduction, T-Lymphocyte Subsets immunology, T-Lymphocyte Subsets metabolism, Transcriptome, Xenograft Model Antitumor Assays, Cytotoxicity, Immunologic genetics, Killer Cells, Natural immunology, Killer Cells, Natural metabolism, Neoplasms immunology, Neoplasms metabolism, Receptors, Antigen, T-Cell metabolism
- Abstract
Background: Adoptive T-cell transfer of therapeutic TCR holds great promise to specifically kill cancer cells, but relies on modifying the patient's own T cells ex vivo before injection. The manufacturing of T cells in a tailor-made setting is a long and expensive process which could be resolved by the use of universal cells. Currently, only the Natural Killer (NK) cell line NK-92 is FDA approved for universal use. In order to expand their recognition ability, they were equipped with Chimeric Antigen Receptors (CARs). However, unlike CARs, T-cell receptors (TCRs) can recognize all cellular proteins, which expand NK-92 recognition to the whole proteome., Methods: We herein genetically engineered NK-92 to express the CD3 signaling complex, and showed that it rendered them able to express a functional TCR. Functional assays and in vivo efficacy were used to validate these cells., Findings: This is the first demonstration that a non-T cell can exploit TCRs. This TCR-redirected cell line, termed TCR-NK-92, mimicked primary T cells phenotypically, metabolically and functionally, but retained its NK cell effector functions. Our results demonstrate a unique manner to indefinitely produce TCR-redirected lymphocytes at lower cost and with similar therapeutic efficacy as redirected T cells., Interpretation: These results suggest that an NK cell line could be the basis for an off-the-shelf TCR-based cancer immunotherapy solution. FUND: This work was supported by the Research Council of Norway (#254817), South-Eastern Norway Regional Health Authority (#14/00500-79), by OUS-Radiumhospitalet (Gene Therapy program) and the department of Oncology at the University of Lausanne., (Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
50. Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity.
- Author
-
Mensali N, Grenov A, Pati NB, Dillard P, Myhre MR, Gaudernack G, Kvalheim G, Inderberg EM, Bakke O, and Wälchli S
- Abstract
Eradication of tumors by the immune system relies on the efficient activation of a T-cell response. For many years, the main focus of cancer immunotherapy has been on cytotoxic CD8 T-cell. However, stimulation of CD4 helper T cells is critical for the promotion and maintenance of immune memory, thus a good vaccine should evoke a two-dimensional T-cell response. The invariant chain (Ii) is required for the MHC class II heterodimer to be correctly guided through the cell, loaded with peptide, and expressed on the surface of antigen presenting cells (APC). We previously showed that by replacing the Ii CLIP peptide by an MHC-I cancer peptide, we could efficiently load MHC-I. This prompted us to test whether longer cancer peptides could be loaded on both MHC classes and whether such peptides could be accommodated in the CLIP region of Ii. We here present data showing that expanding the CLIP replacement size leads to T-cell activation. We demonstrate by using long peptides that APCs can present peptides from the same Ii molecule on both MHC-I and -II. In addition, we present evidence that antigen presentation after Ii-loading was superior to an ER-targeted minigene construct, suggesting that ER-localization was not sufficient to obtain efficient MHC-II loading. Finally, we verified that Ii-expressing dendritic cells could prime CD4
+ and CD8+ T cells from a naïve population. Taken together our study demonstrates that CLIP peptide replaced Ii constructs fulfill some of the major requirements for an efficient vector for cancer vaccination.- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.